Clinical Trials
9 trialsNCT06997029 2026-04-21
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT03065062 2026-02-13
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Suspended
NCT03454035 2025-09-11
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT03498378 2025-04-03
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 1 Active not recruiting
NCT06307249 2024-03-12
PTST_PALBEVA
Lebanese University
Phase 1 Recruiting
NCT06065592 2023-10-06
CAT_PB
Lebanese University
Phase 1 Unknown
NCT01522989 2020-03-04
PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies
Georgetown University
Phase 1 Unknown
NCT02065063 2018-06-01
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00141297 2016-01-05
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Pfizer
Phase 1 Completed